PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 3, 2026Acta Haematologica2 citations

A Case Report of Tyrosine Kinase Inhibitor Interruption in a Patient with Multilineage Philadelphia Positive Acute Lymphoblastic Leukemia

View Full Paper
HGHannah GoulartJBJulie BraishNSNicholas J. Short

Key Points

  • To evaluate the implications of discontinuing tyrosine kinase inhibitor (TKI) therapy in a patient with multilineage Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).
  • Case report analysis of a single patient with Ph+ ALL
  • Assessment of biological characteristics of the disease
  • Monitoring of minimal residual disease (MRD) using next-generation sequencing (NGS)
  • Patient showed deep MRD-negativity
  • TKI interruption raised concerns for disease management
  • Findings suggest the necessity of continuing TKI therapy even in MRD-negative scenarios

Abstract

This case highlights the clinical significance of multilineage Ph+ ALL and its distinct biological background, thereby underscoring caution with TKI discontinuation despite deep NGS MRD-negativity, and may support continued TKI therapy in this setting.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Goulart et al. (2026) studied this question.

synapsesocial.com/papers/69cf5e505a333a821460c9aahttps://doi.org/10.1159/000551699
Ask AI
Helpful
Bookmark
Share
View Full Paper